China VC Weekly: Biotech and Art
China’s colorectal cancer screening leader, New Horizon Health announced the closing of a $30 million Series E financing round.
7/12/20203 min read
Tag: #New Horizon Health
Showing 3 of 3 posts with this tag
Biotech Unicorn New Horizon Health Receives China’s First Early Cancer Screening Approval from NMPA
New Horizon Health on Nov. 25 announced that their flagship product, ColoClear, has been approved by the National Medical Products Administration for the screening of Colorectal Cancer (CRC) and precancerous lesion.
11/27/20203 min read
China’s Cancer Screening Pioneer New Horizon Health Raises HK$2.42 Billion in Hong Kong IPO Debut
On Feb. 18, biotechnology company New Horizon Health (6606.HK) raised HK$2.42 billion in an initial public offering (IPO) in Hong Kong, with the firm’s IPO being oversubscribed 4133 times.